Evidence map›Paper›PMID 38140085›Full record

ArticlePharmaceutics2023

Assessment of Bioprotect's Biodegradable Balloon System as a Rectal Spacer in Radiotherapy: An Animal Study on Tissue Response and Biocompatibility.

Yuval Ramot, Tal Levin-Harrus, Adva Ezratty, Michal Steiner, Nati Ezov, Abraham J Domb, Muhammad Abdel-Haq, Shaul Shohat, Liron Aperman, Lee Adler and 2 more

Abstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuval RamotDepartment of Dermatology, Hadassah Medical Center, Jerusalem 9112001, Israel.ORCID 0000-0002-8606-8385
Tal Levin-HarrusEnvigo CRS Israel Limited, Ness Ziona 7414001, Israel.
Adva EzrattyEnvigo CRS Israel Limited, Ness Ziona 7414001, Israel.
Michal SteinerEnvigo CRS Israel Limited, Ness Ziona 7414001, Israel.
Nati EzovEnvigo CRS Israel Limited, Ness Ziona 7414001, Israel.
Abraham J DombInstitute for Drug Research, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112001, Israel.ORCID 0000-0002-2241-7726
Muhammad Abdel-HaqInstitute for Drug Research, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112001, Israel.
Shaul ShohatBioProtect, Tzur Yigal 4486200, Israel.
Liron ApermanBioProtect, Tzur Yigal 4486200, Israel.
Lee AdlerBioProtect, Tzur Yigal 4486200, Israel.
Oleg DolkartAssuta Ashdod University Hospital, Ben-Gurion University of the Negev, Beer Sheba 8410501, Israel.
Abraham NyskaSackler School of Medicine, Tel Aviv University, Tel Aviv 6200515, Israel.

Funding

BioProtect Ltd
6 · The paper itself

Abstract

Prostate cancer is a significant health concern for men, emphasizing the need for effective treatment strategies. Dose-escalated external beam radiotherapy shows promise in improving outcomes but presents challenges due to radiation effects on nearby structures, such as the rectum. Innovative techniques, including rectal spacers, have emerged to mitigate these effects. This study comprehensively assessed tissue responses following the implantation of the Bioprotect biodegradable fillable balloon as a rectal spacer in a rat model. Evaluation occurred at multiple time points (4, 26, and 52 weeks) post-implantation. Results revealed localized tissue responses consistent with the expected reaction to biodegradable materials, characterized by mild to moderate fibrotic reactions and encapsulation, underscoring the safety and biocompatibility of the balloon. Importantly, no other adverse events occurred, and the animals remained healthy throughout the study. These findings support its potential clinical utility in radiotherapy treatments to enhance patient outcomes and minimize long-term implant-related complications, serving as a benchmark for future similar studies and offering valuable insights for researchers in the field. In conclusion, the findings from this study highlight the safety, biocompatibility, and potential clinical applicability of the Bioprotect biodegradable fillable balloon as a promising rectal spacer in mitigating radiation-induced complications during prostate cancer radiotherapy.

Indexed as

animal modelbiocompitabilitybiodegradable balloonBioprotect balloonprostate cancerradiation therapyradiotherapyrectal spacertissue responsetreatment complications

Identifiers

PMID38140085
PMCPMC10747072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.